News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event
Advancing to IND-enabling studies with multiple drug candidates
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Subscribe To Our Newsletter & Stay Updated
